Study 20 of 33Octreotide literatureEndocrine journal · Observational1994

Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly.

Octreotide treatment resulted in lower GH mRNA levels in adenomas compared to non-treated patients, but the clinical significance of these findings is unclear due to the small sample size.

Read at Endocrine journal Add to compare

Where it sits

this study against the rest of the octreotide corpus

Preclinical

Observational · this one

Open-label

Randomised

Reviews

Summary and findings

Seven patients with growth hormone-secreting pituitary adenoma were treated preoperatively with octreotide and compared with 18 non-treated patients. The octreotide-treated adenomas were reported as soft and easily removed. The amounts of GH mRNA in the adenoma from the octreotide-treated patients were significantly less than those from the non-treated.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →

GH mRNA in octreotide-treated adenomas was 4.2 +/- 1.8 (mean +/- SEM) in arbitrary units.1994

Abstract

The authors’ words, as Endocrine journal supplied them

Seven patients with growth hormone (GH)-secreting pituitary adenoma were treated preoperatively with octreotide (Sandostatin or SMS 201-995; a somatostatin analogue), and were compared with 18 non-treated patients in their clinical courses and adenoma analyses. Octreotide treatment improved the endocrinological data in all 7 cases. The octreotide-treated adenomas were soft and easily removed by suction and curettage. The postoperative normalization of endocrinological data was encountered more often in the octreotide-treated cases than in the non-treated, although the statistical significance was not observed by the limited number of cases. The adenoma tissues were examined with conventional histology and immunohistochemistry, and the amount of GH messenger ribonucleic acid (mRNA) was quantitatively assessed. The studies demonstrated: 1) No fibrosis nor necrosis was observed in the adenomas from the octreotide-treated patients. 2) Immunohistochemistry for human GH revealed no remarkable differences between the octreotide-treated and the non-treated adenomas. 3) The amounts of GH mRNA in the adenoma from the octreotide-treated patients were 4.2 +/- 1.8 (mean +/- SEM; expressed in an arbitrary unit) and were significantly less than those from the non-treated (33.6 +/- 9.1). These data suggest that octreotide inhibits not only GH release from the adenoma but also its biosynthesis.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Octreotide corpus

BManagement of Chylous Acid in Gynecological Malignanciesbiorxiv-preprint · 2026 · On postoperative day 4, median drainage output in TPN-requiring patients was 830 mL.Human CThe role of biorelevant media components on the diffusion and enzymatic stability of oral cyclic peptide analogs.International journal of pharmaceutics · 2026 · Not reported in abstract.In vitro CActivation of the dopamine D2 receptor enhances colonic motility via disinhibition of somatostatinergic signalling in rodents.European journal of pharmacology · 2026 · Not reported in abstract.Animal BMetastatic proinsulin-secreting tumor: a rare cause of persistent hypoglycemia.JCEM case reports · 2023 · n=1 · Not reported in abstract.Human CThe Extent of Ligand-Receptor Interactions for Actively Targeted Nanoparticles as a Function of Ligand Density and Receptor Expression.ACS applied materials & interfaces · 2026 · Not reported in abstract.In vitro ADifferential Somatostatin Sensitivity of Corticotropic and Somatotropic Responses Following Amino Acid Infusion.Endocrine connections · 2026 · Not reported in abstract.Human